VF in the News

Recruiting: Efficacy and Safety of Benralizumab in EGPA compared to Mepolizumab (MANDARA)

Brief Summary:

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy.

All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).

For more information please visit: ClinicalTrials.gov Identifier: NCT04157348
or the AstraZeneca Clinical Trials study site